Reported financial results for the three and twelve months finished December 31 today.

Through the fourth quarters of 2013 and 2012, AcelRx recognized income of $27.6 million and $1.7 million, respectively.4 million of revenue recognized from the $30.0 million upfront payment from Grunenthal and $0.2 million of reimbursement for work completed under a comprehensive research grant from the U.S. Army Medical Study and Materiel Command , for advancement of ARX-04. Fourth quarter of 2012 income contains $1.7 million in reimbursement for work linked to the USAMRMC grant. Study and development expenditures for the quarter ended December 31, 2013 totaled $4.3 million, compared with $7.december 31 8 million for the quarter ended, 2012. Selling, general and administrative expenditures were $3.3 million for the fourth quarter of 2013, weighed against $1.9 million for the fourth quarter of 2012, because of a rise in commercial activities linked to Zalviso primarily, including increased general market trends activities and the initial build of internal marketing capabilities.In our quest to find out the way the brain works, among the fundamental measures is to understand how neurons function, and an individual neuron's shape is a significant contributor to its function in the brain, says Allan Jones, Ph.D., CEO of the Allen Institute for Mind Science. There’s been much exciting function in neuro-scientific digitally reconstructing the shapes of individual neurons, but the community needs requirements in order to both take full advantage of the task we've currently done and to help to make sure that the task we do later on will be of the best possible value. Advances in technology and imaging of individual brain cells have yielded a big library of three-dimensional images of neurons, in addition to dozens of different programs to produce digital reconstructions of the neurons' structures.